<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Pax5 gene encodes the B-cell-specific activator protein which is a key regulator in development and differentiation of B-cell </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the expression of Pax5 in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> to evaluate the diagnostic utility as a B cell marker </plain></SENT>
<SENT sid="2" pm="."><plain>Materials included 70 B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 26 T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 53 <z:hpo ids='HP_0002488'>acute leukemias</z:hpo>, and 6 <z:hpo ids='HP_0006775'>multiple myelomas</z:hpo> (MMs) </plain></SENT>
<SENT sid="3" pm="."><plain>Representative areas from the paraffin embedded tissues were selected for tissue microarray, and the expressions of Pax5 was immunohistochemically evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>Pax5 was strongly expressed in most of the B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>; 44 of 47 diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (93.6%), 15 of 16 marginal zone B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (93.8%), <z:hpo ids='HP_0000001'>all</z:hpo> 3 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 2 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and 2 Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (100%) </plain></SENT>
<SENT sid="5" pm="."><plain>However, Pax5 was expressed in only one of 26 T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Among <z:hpo ids='HP_0001909'>leukemias</z:hpo>, it was expressed in 10 of the 14 B <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemias</z:hpo> (ALLs) (72.4%), but also in 3 of the 6 T ALLs (50%), 13 of the 26 <z:hpo ids='HP_0004808'>acute myelogenous leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AMLs</z:e>) (50%) and in <z:hpo ids='HP_0000001'>all</z:hpo> 3 ALL arising in <z:hpo ids='HP_0005506'>chronic myelogenous leukemias</z:hpo> and 4 mixed <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B ALL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In MMs, Pax5 was negative in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="8" pm="."><plain>We concluded that Pax5 is very useful B cell marker in classification of <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, but not of <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> </plain></SENT>
</text></document>